News & Events
< Back to News Overview
First Australian patient receives C-PulseTM heart assist pump
06 / 06 / 2006
Sunshine Heart's unique heart assist pump called C-PulseTM has been successfully implanted to treat the first Australian patient at St Vincent's Hospital in Sydney last week.
The C-PulseTM, developed by Australian company Sunshine Heart, improves the heart function of patients with heart failure by increasing blood supply to the heart muscle and reducing the heart's pumping work. It is uniquely designed as a non-blood contacting heart-assist device, reducing the risks of clotting and bleeding complications and making it safe to turn the device on and off.
"Our first theatre experience with the C-PulseTM has been very positive. The operation was without complication and the patient has recovered well postoperatively," said Dr Paul Jansz, principal investigator and Consultant Cardiothoracic Surgeon at St Vincent's Hospital, Sydney who led the pioneering Australian team.
"The surgery was completed without the need for bypass in less than two hours. This week the patient continues his recovery and we are seeing the benefit from the device's action. We are very pleased with these initial results."
Dr Christopher Hayward, Consultant Cardiologist St Vincent's Hospital, Sydney added: "Implantation of the C-PulseT device was considered to be the best option for the patient, who has suffered heart failure for more than 5 years."
"The C-Pulse is unique because it doesn't touch the blood and can be turned off for showering and other activities. It provides both the additional circulatory support needed and the freedom to disconnect from the device if the patient desires. We are continuing the assessment of the C-Pulse with follow-up measurements of quality of life and heart function," Dr Hayward explained.
Dr Hayward further indicated that following this initial implant, new patients will continue to be identified and recruited for this heart failure clinical trial.
Dr William Peters, Medical Director of Sunshine Heart concluded. "We're delighted that St Vincent's Hospital has implanted the C-PulseTM in the first Australian recipient. The commencement of the trial in Australia is terrific news as the CPulse T offers to improve the quality of life for people with moderate to severe heart failure who currently receive limited benefit from existing therapies".
This implant is part of a multi-centre trial in Australia and New Zealand involving up to ten patients being conducted at Auckland City Hospital (Auckland), the Alfred Hospital (Melbourne), Southern Health Monash Medical Centre (Melbourne) and St Vincent's Hospital (Sydney).
The C-PulseTM, developed by Australian company Sunshine Heart, improves the heart function of patients with heart failure by increasing blood supply to the heart muscle and reducing the heart's pumping work. It is uniquely designed as a non-blood contacting heart-assist device, reducing the risks of clotting and bleeding complications and making it safe to turn the device on and off.
"Our first theatre experience with the C-PulseTM has been very positive. The operation was without complication and the patient has recovered well postoperatively," said Dr Paul Jansz, principal investigator and Consultant Cardiothoracic Surgeon at St Vincent's Hospital, Sydney who led the pioneering Australian team.
"The surgery was completed without the need for bypass in less than two hours. This week the patient continues his recovery and we are seeing the benefit from the device's action. We are very pleased with these initial results."
Dr Christopher Hayward, Consultant Cardiologist St Vincent's Hospital, Sydney added: "Implantation of the C-PulseT device was considered to be the best option for the patient, who has suffered heart failure for more than 5 years."
"The C-Pulse is unique because it doesn't touch the blood and can be turned off for showering and other activities. It provides both the additional circulatory support needed and the freedom to disconnect from the device if the patient desires. We are continuing the assessment of the C-Pulse with follow-up measurements of quality of life and heart function," Dr Hayward explained.
Dr Hayward further indicated that following this initial implant, new patients will continue to be identified and recruited for this heart failure clinical trial.
Dr William Peters, Medical Director of Sunshine Heart concluded. "We're delighted that St Vincent's Hospital has implanted the C-PulseTM in the first Australian recipient. The commencement of the trial in Australia is terrific news as the CPulse T offers to improve the quality of life for people with moderate to severe heart failure who currently receive limited benefit from existing therapies".
This implant is part of a multi-centre trial in Australia and New Zealand involving up to ten patients being conducted at Auckland City Hospital (Auckland), the Alfred Hospital (Melbourne), Southern Health Monash Medical Centre (Melbourne) and St Vincent's Hospital (Sydney).